Publicaciones en las que colabora con Isabel Lastres Becker (24)

2022

  1. New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

    Biomolecules, Vol. 12, Núm. 9

2021

  1. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

    Acta Neuropathologica Communications, Vol. 9, Núm. 1

2010

  1. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice

    PLoS ONE, Vol. 5, Núm. 7, pp. 1-15

2009

  1. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

    GLIA, Vol. 57, Núm. 11, pp. 1154-1167

2006

  1. An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments

    Current Medicinal Chemistry, Vol. 13, Núm. 30, pp. 3705-3718

2005

  1. Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice

    Brain Research, Vol. 1046, Núm. 1-2, pp. 195-206

  2. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease

    Neurobiology of Disease, Vol. 19, Núm. 1-2, pp. 96-107

2004

  1. Involvement of the endocannabinoid system in motor disorders

    Current Medicinal Chemistry - Central Nervous System Agents, Vol. 4, Núm. 3, pp. 175-182

  2. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence

    Brain Research, Vol. 1007, Núm. 1-2, pp. 152-159

  3. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo

    NeuroReport, Vol. 15, Núm. 15, pp. 2375-2379

2003

  1. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease

    Journal of Neurochemistry, Vol. 84, Núm. 5, pp. 1097-1109

  2. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate

    NeuroReport, Vol. 14, Núm. 6, pp. 813-816

  3. The endocannabinoid system and Huntington's disease.

    Current drug targets. CNS and neurological disorders, Vol. 2, Núm. 5, pp. 335-347

2002

  1. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease

    Synapse, Vol. 44, Núm. 1, pp. 23-35

  2. Endocannabinoids and basal ganglia functionality

    Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 66, Núm. 2-3, pp. 257-267

  3. Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease

    Neurotoxicity Research, Vol. 4, Núm. 7-8, pp. 601-608

  4. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease

    Brain Research, Vol. 929, Núm. 2, pp. 236-242

  5. The endogenous cannabinoid system and the basal ganglia: Biochemical, pharmacological, and therapeutic aspects

    Pharmacology and Therapeutics, Vol. 95, Núm. 2, pp. 137-152

2001

  1. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration

    Journal of Neurochemistry, Vol. 78, Núm. 6, pp. 1415-1427

  2. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease

    NeuroReport, Vol. 12, Núm. 10, pp. 2125-2129